Carregant...
TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABA(A) receptor agonist mechanism: possible therapeutic target for cognitive deficit in schizophrenia
GABAergic drugs are of interest for the treatment of anxiety, depression, bipolar disorder, pain, cognitive impairment associated with schizophrenia (CIAS), and other neuropsychiatric disorders. Some evidence suggests that TPA-023, (7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2...
Guardat en:
| Publicat a: | Neuropsychopharmacology |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer International Publishing
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6180114/ https://ncbi.nlm.nih.gov/pubmed/30093697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41386-018-0160-3 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|